Indication
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild- type, an anti-EGFR therapy. It is also use to treat metastaticgastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
Note
Precaution
- Nublexa is a prescription drug and should be used under proper medical guidance and advice.
- Control hypertension before initiating treatment; monitor blood pressure regularly during treatment.
- Advise females & males of reproductive potential to use effective contraception during treatment and for 2 months after final dose.
- Increases risk for hemorrhage; discontinue therapy for severe or life-threatening hemorrhage.
